Roberto Chiarle, MD
Hematopathology, Department of Pathology
Professor in Pathology, Harvard Medical School
Image
Roberto Chiarle, MD
Hematopathology, Department of Pathology
Professor in Pathology, Harvard Medical School
Medical Services
Languages
English
Education
Medical School
University of Torino Medical School
1993
Torino
Italy
Residency
Anatomic Pathology
University of Torino Medical School
1997
Torino
Italy
Fellowship
Hematology and Molecular Pathology
New York University Medical Center
2001
New York
NY
Publications
Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. View Abstract
HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy. View Abstract
Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood. View Abstract
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. View Abstract
ALK in cancer: from function to therapeutic targeting. View Abstract
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma. View Abstract
HSP and CD279 gene expression as candidate biomarkers in symptomatic LGLL patients. View Abstract
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma. View Abstract
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. View Abstract
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells. View Abstract
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. View Abstract
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. View Abstract
Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma. View Abstract
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. View Abstract
Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia. View Abstract
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. View Abstract
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. View Abstract
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment. View Abstract
Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers. View Abstract
Correction: The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. View Abstract
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia. View Abstract
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. View Abstract
Targeting CCR7-PI3K? overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. View Abstract
ERa-associated translocations underlie oncogene amplifications in breast cancer. View Abstract
A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia. View Abstract
DNA repair mechanisms that promote insertion-deletion events during immunoglobulin gene diversification. View Abstract
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas. View Abstract
Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. View Abstract
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma. View Abstract
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases. View Abstract
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. View Abstract
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. View Abstract
Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy. View Abstract
Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. View Abstract
Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. View Abstract
Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. View Abstract
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. View Abstract
Deletion of murine Rhoh leads to de-repression of Bcl-6 via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma. View Abstract
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. View Abstract
Solving the chromosome puzzle of aneuploidy in cancer. View Abstract
IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. View Abstract
Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. View Abstract
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. View Abstract
A LIBRETTO to orchestrate targeted therapy. View Abstract
High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. View Abstract
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. View Abstract
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. View Abstract
CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. View Abstract
RHO Family GTPases in the Biology of Lymphoma. View Abstract
Comment on "ALK is a therapeutic target for lethal sepsis". View Abstract
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. View Abstract
Parp3 promotes long-range end joining in murine cells. View Abstract
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. View Abstract
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. View Abstract
The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo. View Abstract
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2a Scaffolding Function. View Abstract
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. View Abstract
Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. View Abstract
A Braf kinase-inactive mutant induces lung adenocarcinoma. View Abstract
Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. View Abstract
Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. View Abstract
Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature. View Abstract
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. View Abstract
Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. View Abstract
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. View Abstract
Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. View Abstract
Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. View Abstract
Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. View Abstract
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. View Abstract
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. View Abstract
Advances in cancer immunology and cancer immunotherapy. View Abstract
Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. View Abstract
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. View Abstract
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. View Abstract
The anaplastic lymphoma kinase as an oncogene in solid tumors. View Abstract
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. View Abstract
A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. View Abstract
Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. View Abstract
Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. View Abstract
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. View Abstract
STAT3ß controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. View Abstract
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. View Abstract
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. View Abstract
IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. View Abstract
FuseFISH: robust detection of transcribed gene fusions in single cells. View Abstract
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. View Abstract
Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. View Abstract
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. View Abstract
Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. View Abstract
STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. View Abstract
Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. View Abstract
Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. View Abstract
Translocations in normal B cells and cancers: insights from new technical approaches. View Abstract
The battle against ALK resistance: successes and setbacks. View Abstract
Calming down T cell acute leukemia. View Abstract
FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. View Abstract
Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. View Abstract
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. View Abstract
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. View Abstract
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. View Abstract
Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. View Abstract
Mechanisms that promote and suppress chromosomal translocations in lymphocytes. View Abstract
PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. View Abstract
Expression of IFN?R2 mutated in a dileucine internalization motif reinstates IFN? signaling and apoptosis in human T lymphocytes. View Abstract
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. View Abstract
Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. View Abstract
MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. View Abstract
The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. View Abstract
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? View Abstract
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. View Abstract
IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. View Abstract
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. View Abstract
IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. View Abstract
Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. View Abstract
Anaplastic lymphoma kinase: an oncogene for tumor vaccination. View Abstract
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. View Abstract
Heat shock protein expression in diabetic nephropathy. View Abstract
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. View Abstract
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. View Abstract
Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. View Abstract
High energy shock waves (HESW) increase paclitaxel efficacy in a syngeneic model of breast cancer. View Abstract
An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. View Abstract
The anaplastic lymphoma kinase in the pathogenesis of cancer. View Abstract
Autoantibody signature in human ductal pancreatic adenocarcinoma. View Abstract
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. View Abstract
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. View Abstract
The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. View Abstract
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. View Abstract
Conditional activation of MET in differentiated skeletal muscle induces atrophy. View Abstract
In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. View Abstract
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. View Abstract
Incestuous paternity detected by STR-typing of chorionic villi isolated from archival formalin-fixed paraffin-embedded abortion material using laser microdissection. View Abstract
New and old functions of STAT3: a pivotal target for individualized treatment of cancer. View Abstract
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. View Abstract
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. View Abstract
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. View Abstract
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. View Abstract
RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. View Abstract
The STAT3 isoforms alpha and beta have unique and specific functions. View Abstract
Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. View Abstract
Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. View Abstract
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. View Abstract
Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. View Abstract
Role of CD30 in the maturation of thymocytes and in the pathogenesis of autoimmune diseases. View Abstract
Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas. View Abstract
In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. View Abstract
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. View Abstract
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. View Abstract
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. View Abstract
Role of the F-box protein Skp2 in lymphomagenesis. View Abstract
Induction of germinal centers by MMTV encoded superantigen on B cells. View Abstract
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. View Abstract
Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. View Abstract
Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. View Abstract
Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). View Abstract
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. View Abstract
Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. View Abstract
CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. View Abstract
CD30 in normal and neoplastic cells. View Abstract
Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. View Abstract
Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL). View Abstract
Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. View Abstract
p53 expression and proliferative activity predict survival in non-invasive thymomas. View Abstract
Long-term survival of thymoma patients by histologic pattern and proliferative activity. View Abstract
Identification of the same HRAS1 mutation in a primary minimally invasive follicular carcinoma of the thyroid gland and its bone metastasis developed 15 years later. View Abstract
Argyrophilic nucleolar organizer region counts predict survival in thymoma. View Abstract
Locations